Treatment and outcome of systemic lupus erythematosus (SLE) in C1q deficient patients are rarely reported. The aim of this report is to share our experience about the course of management of three cases diagnosed as SLE with C1q deficiency, in light of present literature. Initial and dominant complaints of three cases from two different families were cutaneous manifestations. One patient was also diagnosed with arthritis and thrombocytopenia. Antinuclear antibody was positive in all cases, whereas anti-dsDNA was negative with normal levels of complement C3, C4 and decreased CH50 activity. C1QA gene of two patients had homozygous nonsense mutation (c.622 > T/p.Gln208Ter). Previously, all of them had been treated with steroids, hydroxychloroquine and methotrexate or azathioprine. It was learned that they had responded only to high dosage prednisolone and their symptoms flared up during dosage reduction even under methotrexate or azathioprine. All symptoms of all three cases improved by daily fresh frozen plasma (FFP) infusions, and once cutaneous lesions subsided, the infusions were reduced to a frequency that would prevent the flare up of the symptoms. Literature search revealed seven reports on fresh frozen plasma treatment in SLE with C1q deficient patients. In this report, it is concluded that severe cutaneous lesions, as seen in these C1q deficient SLE patients, cannot be controlled with conventional immunosuppressive treatment. Instead, regular fresh frozen plasma infusions are proposed as a more reasonable method of treatment. Lupus (2018) 27, 134-138.
Introduction
C1q deficiency is a rare cause of early onset childhood systemic lupus erythematosus (SLE). 1, 2 There are fewer than 100 reported cases, with only a few reports on follow-up and treatment of this disease, which include deaths and successes. [3] [4] [5] [6] Although allogenic hematopoietic stem cell transplantation shows promise for the future, currently it seems highly risky. [7] [8] [9] Regular fresh frozen plasma (FFP) infusion is rarely reported as a safe and effective treatment method. 10, 11 In this report, the efficacy of FFP treatment in SLE with C1q deficiency patients is discussed in the light of present literature.
Case 1
Clinical information of case 1 is presented in Table 1 . [10] [11] [12] [13] [14] [15] A five-year-old boy presented with oral ulcers, rash/desquamation in his face, extremities, palms, soles, and fingers. His parents are first cousins. Prednisolone at a dosage of 2 mg/kg per day was effective for the relief of all symptoms. Lesions flared up during prednisolone reduction, even under methotrexate and hydroxychloroquine. Complement C3 and C4 levels were normal. CH50 activity was 35% (70-140) and complement C1q level was <6 mg/l (118-238). A homozygous nonsense mutation (c.622 > T/p.Gln208Ter) was detected in the C1QA gene. FFP infusions at a dosage of 10 ml/kg for three consecutive days were effective, and cutaneous lesions and oral ulcers disappeared immediately. Methotrexate and prednisolone were discontinued, but hydroxychloroquine was continued. FFP infusions gradually reduced. The administration of FFP treatment 
Case 2
Clinical information of case 2 is presented in Table 1 . A 4.5-year-old boy presented with rash/desquamation in his face, extremities, palms, soles, and fingers and short stature with Cushing-like appearance. His parents are first cousins, and his sister (case 3) has the same symptoms. He has been treated for SLE from the age of six months. Prednisolone at a dosage of 2 mg/kg per day was effective for the relief of all symptoms. He has been on prednisolone for the last four years. Cutaneous lesions flared up during prednisolone reduction even under methotrexate and hydroxychloroquine. Complement C3 and C4 levels were normal. CH50 activity (27% (40-130)) sustained the diagnosis of deficiency of one of the early complement components. A homozygous nonsense mutation (c.622 > T/p.Gln208Ter) was detected in the C1QA gene. Daily FFP infusions at a dosage of 10 ml/kg for five consecutive days were effective and cutaneous lesions disappeared. Methotrexate and prednisolone were discontinued, but hydroxychloroquine was continued. FFP infusions were gradually reduced. Weekly FFP treatment was successful. However, his family stopped the treatment for two weeks. After the two weeks, he presented with arthritis, severe cutaneous manifestations, anemia, and thrombocytopenia. He was symptom free immediately after three consecutive daily FFP infusions. Now he has been symptom free under weekly FFP treatment for 3.5 years.
Case 3
Clinical information of case 3 is presented in Table1. A 10-year-old girl presented with oral ulcers and rash, and desquamation in her face and arms. Her parents are cousins and her brother (case 2) has the same symptoms. She has been treated for SLE from the age of three years. She was on prednisolone for seven years. Prednisolone at a dosage of 2 mg/kg per day was effective for the relief of the cutaneous lesions. Lesions flared during prednisolone reduction even under methotrexate and hydroxychloroquine. Bone mineral density revealed a low z score (-2.7) for her age and sex. Complement C3 and C4 levels were normal. CH50 activity was 29% (40-130). Daily FFP infusions at a dosage of 10 ml/kg for three consecutive days were effective, and cutaneous and oral lesions disappeared. Methotrexate and prednisolone were discontinued, but hydroxychloroquine was continued. FFP infusions were gradually reduced. Weekly FFP treatment was successful. However, her family stopped the treatment for two weeks. Afterwards, she presented with severe cutaneous lesions. She responded well to daily FFP treatment, and she has been symptom free under weekly FFP treatment for 3.5 years. As an adolescent she sometimes delays the FFP treatment and cutaneous lesions severely flare.
Discussion
In this report, we have presented three cases of early onset SLE with C1q deficiency. Their common feature is steroid dependent severe cutaneous lesions. Two out of three had findings of steroid toxicity. Hereditary deficiency of early complement components, mainly C1q deficiency, is one of the reasons for early-onset SLE. Cutaneous manifestations are a distinct feature of early-onset SLE. 16 C1q binds to apoptotic debris and accelerates the removal of auto antigens and immune complexes. Overactive apoptosis of keratinocytes upon sun exposure and diminished clearance of the debris is the main cause of cutaneous manifestations in C1q deficiency. 17 Although rare, clinical presentation and diseasecausing mutations about hereditary C1q deficiency has been the subject of reviews. 3, 4, 18 Mostly recurrent encapsulated bacterial infections and/or SLE are the clinical forms of presentation, but unaffected individuals are also reported. 4, 19 The preferred method of treatment of these patients mainly included corticosteroids, other immunosuppressive drugs (mostly alkylating agents) and antibiotics if required. High dosage of corticosteroids is effective but flare-ups during dosage reduction or withdrawal are also reported, as seen in our patients. 5, 15, 20 There is also a lack of information about efficacy of hydroxychloroquine and other immunosuppressive drugs such as azathioprine and mizorubine. There are some reports of death because of ineffectiveness of these drugs during flare ups. 5, 6 There are a few reports regarding FFP treatment, but only two of these offer some promise. 10, 11 However, our literature review revealed that experts dealing with C1q deficiency did not rate this treatment modality as highly as expected.
C1q deficiency and fresh frozen plasma Z Ekinci and K Ozturk
The first report about usage of FFP is by Berkel et al. 12 He mentioned immediate improvement of a C1q deficient SLE-like patient with three consecutive plasma exchanges with FFP. In 1993 Kirschfink et al. 13 mentioned FFP induced severe immediate allergic reaction in a severe SLE with C1q deficiency patient. A PubMed search regarding FFP treatment in SLE with C1q deficient patients revealed seven reports. Six of them are case reports and only two reports described the dosage, interval, duration, and efficacy in detail; the other four only very briefly mention the usage of FFP. The current report with three cases will be the third welldescribed FFP treatment with dosage, interval, duration, and efficacy in SLE with C1q deficiency patients. These reports are presented in Table 1 . [10] [11] [12] [13] [14] [15] A common feature of these cases was unresponsiveness to the immunosuppressive treatment. The seventh report -not shown in the table -is about the clinical follow-up of C1q deficient individuals. It was a search performed by a questionnaire to the clinicians dealing with C1q deficient patients. 4 Fourteen out of 45 patients included in that study were reported to be treated with FFP. However, the success rate of FFP over immunosuppressive therapy is missing. Another important unanswered question is the preference of first line treatment modality. Side effects of long term immunosuppressive drugs and side effects of regular FFP treatment should be considered.
Taking nucleic acid amplification testing and all other donor-screening activities into account, a current estimate of the risk of transfusion-associated infections is considerably low. Acute hemolytic reactions are extremely unlikely. Hypocalcemia (caused by sodium citrate in FFP) and transfusion-related acute lung injury are rarely reported side effects of FFP infusion. 21 Only case 2 presented itchy reactions a few times during FFP infusion and these reactions were very well controlled with an intramuscular antihistaminic injection. We did not observe any other side effects during follow-up.
Heterogeneity of clinical presentation and severity of symptoms also complicated the evaluation of the efficacy of the treatment. Even our three patients with the same homozygous nonsense mutation presented with differences in age of onset, severity of lesions, and need of FFP.
A limitation of this report is the unknown status of the patients regarding anti-C1q antibodies. A significant association has been reported with anti-C1q antibodies and renal involvement in SLE patients. 22 For now, we can speculate that our patients did not develop anti-C1q antibodies because they do not have any sign of renal involvement and also FFP infusions are still effective on the clinical bases.
It is understood that administration of FFP normalizes C1q level for a very short period, but the efficacy of FFP on CH50 or CH100 activity persists for 2-7 days. Clinical efficacy persists from one week up to three weeks. 10, 11 It is concluded that severe cutaneous lesions, as seen in these C1q deficient SLE patients, cannot be controlled with conventional immunosuppressive treatment. Instead, regular FFP infusions are proposed as a more reasonable method of treatment.
